Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / IMAB - Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between 2 San Diego-China Oncology Biopharmas

IMAB - Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between 2 San Diego-China Oncology Biopharmas

I-MAB
  • Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Sorrento will pay $38 million upfront in stock and make up to an additional $450 million in milestones payments.
  • Beijing's BeiGene was approved to manufacture the company's approved anti-PD-1 antibody at its new Guangzhou facility.
  • Invesco has launched a new China Healthcare Equity fund to offer a diversified portfolio of China-listed healthcare companies.

For further details see:

Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between 2 San Diego-China Oncology Biopharmas
Stock Information
Company Name: I-MAB
Stock Symbol: IMAB
Market: NASDAQ
Website: i-mabbiopharma.com
Menu
IMAB IMAB Quote IMAB Short IMAB News IMAB Articles IMAB Message Board
Get IMAB Alerts

News, Short Squeeze, Breakout and More Instantly...